Sponsor: Kangpu Biopharmaceuticals, Ltd.
KPG-121-101: A study using KPG-121 plus enzalutamide for patients with Metastatic Castration-Resistant Prostate cancer whose PSA has failed, after 3 months, to respond to treatment with enzalutamide alone.
For more information please contact the clinical research department: 631-675-5075